Myeloid Protease-Activated Receptor-2 Contributes to Influenza A Virus Pathology in Mice.

Animals Cytokines / analysis Female Influenza A virus Interferon-beta / biosynthesis Lung / pathology Male Mice Mice, Inbred C57BL Myeloid Cells / physiology Neutrophils / immunology Orthomyxoviridae Infections / immunology Receptor, PAR-2 / deficiency
F2rl1 influenza A virus innate immune response lung epithelial cell macrophage protease-activated receptor 2 (PAR2) toll-like receptor 3

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 07 10 2021
accepted: 12 11 2021
entrez: 20 12 2021
pubmed: 21 12 2021
medline: 10 2 2022
Statut: epublish

Résumé

Innate immune responses to influenza A virus (IAV) infection are initiated in part by toll-like receptor 3 (TLR3). TLR3-dependent signaling induces an antiviral immune response and an NFκB-dependent inflammatory response. Protease-activated receptor 2 (PAR2) inhibits the antiviral response and enhances the inflammatory response. PAR2 deficiency protected mice during IAV infection. However, the PAR2 expressing cell-types contributing to IAV pathology in mice and the mechanism by which PAR2 contributes to IAV infection is unknown. IAV infection was analyzed in global ( After IAV infection, Global

Sections du résumé

Background
Innate immune responses to influenza A virus (IAV) infection are initiated in part by toll-like receptor 3 (TLR3). TLR3-dependent signaling induces an antiviral immune response and an NFκB-dependent inflammatory response. Protease-activated receptor 2 (PAR2) inhibits the antiviral response and enhances the inflammatory response. PAR2 deficiency protected mice during IAV infection. However, the PAR2 expressing cell-types contributing to IAV pathology in mice and the mechanism by which PAR2 contributes to IAV infection is unknown.
Methods
IAV infection was analyzed in global (
Results
After IAV infection,
Conclusion
Global

Identifiants

DOI: 10.3389/fimmu.2021.791017 PMID: 34925374 PMC: PMC8671937
pubmed: 34925374
doi: 10.3389/fimmu.2021.791017
pmc: PMC8671937
doi:

Substances chimiques

Cytokines 0
Receptor, PAR-2 0
Interferon-beta 77238-31-4

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

791017

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL142799
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL155657
Pays : United States

Informations de copyright

Copyright © 2021 Gunther, Bharathi, Miles, Tumey, Schmedes, Tatsumi, Bridges, Martinez, Montgomery, Beck, Camerer, Mackman and Antoniak.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Am J Respir Cell Mol Biol. 2019 Mar;60(3):335-345
pubmed: 30290124
Physiol Rep. 2016 Dec;4(24):
pubmed: 28003564
J Pharmacol Exp Ther. 1999 Feb;288(2):671-8
pubmed: 9918574
Nature. 2011 Jun 15;474(7351):337-42
pubmed: 21677750
J Thromb Haemost. 2016 Jun;14(6):1238-48
pubmed: 26947929
Immunity. 2007 Aug;27(2):240-52
pubmed: 17723216
Adv Exp Med Biol. 2021;1322:195-218
pubmed: 34258742
Arch Virol. 1996;141(10):1979-89
pubmed: 8920829
Arch Biochem Biophys. 2019 Mar 30;664:167-173
pubmed: 30677406
Crit Care. 2019 Jul 19;23(1):258
pubmed: 31324202
Vaccines (Basel). 2021 Jun 04;9(6):
pubmed: 34199803
J Gen Virol. 2017 Oct;98(10):2401-2412
pubmed: 28884667
Int J Mol Sci. 2021 May 29;22(11):
pubmed: 34072295
Mucosal Immunol. 2010 Jan;3(1):29-39
pubmed: 19865078
Mol Cell Biol. 2016 Dec 19;37(1):
pubmed: 27795299
Am J Physiol Lung Cell Mol Physiol. 2004 Feb;286(2):L388-98
pubmed: 14633513
Clin Exp Allergy. 2015 Dec;45(12):1844-55
pubmed: 26312432
Res Pract Thromb Haemost. 2020 Dec 06;5(1):17-26
pubmed: 33537526
Blood. 2014 Apr 24;123(17):2605-13
pubmed: 24632711
J Exp Med. 2001 Jan 1;193(1):101-10
pubmed: 11136824
J Virol. 2013 Feb;87(3):1811-20
pubmed: 23192872
Annu Rev Immunol. 2003;21:335-76
pubmed: 12524386
J Clin Invest. 2013 Mar;123(3):1310-22
pubmed: 23391721
Tissue Barriers. 2021 Sep 11;:1968763
pubmed: 34511032
Br J Pharmacol. 2021 Jul 7;:
pubmed: 34235728
Respir Res. 2016 May 23;17(1):62
pubmed: 27215903
PLoS Pathog. 2006 Jun;2(6):e53
pubmed: 16789835
Open Forum Infect Dis. 2019 Oct 29;6(11):ofz462
pubmed: 32258201
J Thromb Thrombolysis. 2021 Aug;52(2):391-396
pubmed: 33893900
PLoS Med. 2021 Mar 1;18(3):e1003550
pubmed: 33647033
Sci Immunol. 2019 Sep 20;4(39):
pubmed: 31541031
Virology. 2020 Jan 15;540:17-22
pubmed: 31731106
Cell Syst. 2018 Jun 27;6(6):679-691.e4
pubmed: 29886109
Clin Sci (Lond). 2017 Feb 1;131(4):269-283
pubmed: 28108632
Cardiovasc Res. 2011 Feb 15;89(3):595-603
pubmed: 21084314
Am J Respir Crit Care Med. 2016 Apr 15;193(8):847-60
pubmed: 26599507
J Immunol Methods. 2014 Jun;408:89-100
pubmed: 24857755
Science. 2020 Aug 7;369(6504):712-717
pubmed: 32527928
Am J Respir Cell Mol Biol. 2016 Jan;54(1):60-70
pubmed: 26072921
J Thromb Haemost. 2021 Jan;19(1):161-172
pubmed: 33064371
J Virol. 2015 Dec 16;90(5):2536-43
pubmed: 26676790
J Virol. 2015 Sep;89(18):9383-92
pubmed: 26136565
PLoS One. 2015 Jun 26;10(6):e0131451
pubmed: 26115403
Biochem J. 2005 Jun 15;388(Pt 3):967-72
pubmed: 15537383
J Immunol. 2019 Jul 15;203(2):441-452
pubmed: 31182479
J Virol. 2013 Apr;87(8):4237-51
pubmed: 23365447
Molecules. 2021 Feb 04;26(4):
pubmed: 33557246
J Immunol. 2008 May 15;180(10):6903-10
pubmed: 18453611
Mucosal Immunol. 2008 Mar;1(2):156-68
pubmed: 19079173
J Biol Chem. 2008 Sep 5;283(36):24314-25
pubmed: 18622013
Cell Immunol. 2019 Oct;344:103949
pubmed: 31337508
J Exp Med. 2008 Dec 22;205(13):3065-77
pubmed: 19064696
J Am Coll Cardiol. 2013 Nov 5;62(19):1737-45
pubmed: 23871888
J Virol. 2020 Apr 16;94(9):
pubmed: 32051270
Am J Physiol Heart Circ Physiol. 2014 Sep 15;307(6):H922-32
pubmed: 25038143
J Pharmacol Exp Ther. 2012 Dec;343(3):725-35
pubmed: 22988062
PLoS Pathog. 2013 Feb;9(2):e1003188
pubmed: 23468627
J Thromb Haemost. 2021 Apr;19(4):1103-1111
pubmed: 33346953
Blood Adv. 2020 Nov 24;4(22):5810-5824
pubmed: 33232477
Nature. 2020 Oct;586(7830):560-566
pubmed: 32854108
J Immunol. 2009 Jun 15;182(12):7795-802
pubmed: 19494303
Am J Physiol Lung Cell Mol Physiol. 2013 Apr 1;304(7):L481-8
pubmed: 23355384
J Immunol. 2002 Nov 1;169(9):5315-21
pubmed: 12391252
J Innate Immun. 2017;9(2):181-192
pubmed: 27820939
J Virol. 2008 May;82(9):4265-74
pubmed: 18287245
J Med Invest. 2011 Feb;58(1-2):19-28
pubmed: 21372483
BMC Physiol. 2007 Mar 30;7:4
pubmed: 17397548
J Virol. 2019 Mar 5;93(6):
pubmed: 30626688
J Vis Exp. 2020 Aug 6;(162):
pubmed: 32831298
Blood Adv. 2021 Jul 13;5(13):2760-2774
pubmed: 34242391
Antiviral Res. 1994 Feb;23(2):107-18
pubmed: 7511880
Biomed Res Int. 2013;2013:879080
pubmed: 24171176
J Vis Exp. 2019 Jan 26;(143):
pubmed: 30741258
Nat Rev Immunol. 2014 May;14(5):315-28
pubmed: 24762827
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11531-6
pubmed: 20534532
PLoS Pathog. 2014 Apr 03;10(4):e1004053
pubmed: 24699679
PLoS Pathog. 2011 Feb;7(2):e1001304
pubmed: 21383977
J Cardiovasc Transl Res. 2014 Mar;7(2):203-11
pubmed: 24203054

Auteurs

Randall C Gunther (RC)

UNC Blood Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Vanthana Bharathi (V)

UNC Blood Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Stephen D Miles (SD)

UNC Blood Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Lauryn R Tumey (LR)

UNC Blood Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Clare M Schmedes (CM)

UNC Blood Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Kohei Tatsumi (K)

UNC Blood Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Meagan D Bridges (MD)

UNC Blood Research Center, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

David Martinez (D)

UNC Blood Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Stephanie A Montgomery (SA)

UNC Lineberger Comprehensive Cancer Center, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Melinda A Beck (MA)

Department of Nutrition, Gillings School of Global Public Health, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Eric Camerer (E)

Department of Medicine, Université de Paris, Paris Cardiovascular Research Center (PARCC), INSERM UMR 970, Paris, France.

Nigel Mackman (N)

UNC Blood Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Silvio Antoniak (S)

UNC Blood Research Center, UNC Lineberger Comprehensive Cancer Center, UNC McAllister Heart Institute, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Myeloid Protease-Activated Receptor-2...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Myeloid Protease-Activated Receptor-2...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Orthomyxoviridae › Influenzavirus A › Virus de la grippe A › Myeloid Protease-Activated Receptor-2...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Interféron de type I › Interféron bêta › Myeloid Protease-Activated Receptor-2...
questionsmedicales.fr › Appareil respiratoire › Poumon › Myeloid Protease-Activated Receptor-2...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Myeloid Protease-Activated Receptor-2...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Myeloid Protease-Activated Receptor-2...
questionsmedicales.fr › Cellules › Cellules myéloïdes › Myeloid Protease-Activated Receptor-2...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Granulocytes neutrophiles › Myeloid Protease-Activated Receptor-2...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Infections à Orthomyxoviridae › Myeloid Protease-Activated Receptor-2...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs activés par la protéinase › Récepteur de type PAR-2 › Myeloid Protease-Activated Receptor-2...